Orexigen Therapeutics Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 13 of 13 Posts
Orexigen Files For Chapter 11 Bankruptcy
Article By: The Fly Monday, March 12, 2018 8:44 AM EDT
Orexigen Therapeutics announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
In this article: OREX
Read
Orexigen Rises After Update On 2017 Priorities
Article By: The Fly Thursday, January 5, 2017 5:36 PM EDT
Shares of Orexigen Therapeutics are on the rise after the company provided an update on recent progress and its key business priorities for 2017 to boost the sales of its two diet pill products, Contrave and Mysimba.
In this article: OREX Also: VRX
Read
Morning Call For October 12, 2015
Article By: Jim Van Meerten Monday, October 12, 2015 11:00 AM EDT
A short review of what's happening in the markets and the world of finance and the economy today.
In this article: CS, DRI, EMC, NOC, RL, RTN, SXC, OREX, ABCO, BWLD, MLHR, TECD, TWTR, SIEN, RDUS
Read
5 Sell-Ranked Biotechs That Fell More Than 5% Today
Article By: Zacks Investment Research Friday, September 25, 2015 7:12 PM EDT
Despite being one of the most successful sectors in the past few years, the biotech sector has been struggling as of late. Friday was an especially tough day for many biotech stocks with 5 that suffered losses of at least 5% on the day.
In this article: ACAD, OREX, ALDR, ANIP, BLUE
Read
E Orexigen Keeps Getting Slammed On Negative News
Article By: Terry Chrisomalis Tuesday, May 12, 2015 8:10 PM EDT
Two negative pieces of news came out today, leading Orexigen's share price lower
In this article: OREX, TKPHF
Read
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis Tuesday, March 3, 2015 2:37 PM EDT
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports Tuesday, February 10, 2015 5:59 AM EDT
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market
Article By: Terry Chrisomalis Friday, December 26, 2014 3:58 PM EDT
Saxenda Approved by the FDA to treat Obesity but faces big obstacles against many competitors.
In this article: NVO, TKPHF, OREX, ARNA, VVUS
Read
Orexigen Received The FDA's Approval For Contrave Yet Questions Remain
Article By: Dr. Hung Tran Thursday, September 11, 2014 6:33 PM EDT
The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?
In this article: GSK, ARNA, OREX, VVUS
Read
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind
Article By: Dr. Hung Tran Tuesday, August 19, 2014 1:10 PM EDT
360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid. Stock promoters who were overly exuberant on Arena, Orexigen, and/or VIVUS mislead investors.
In this article: ARNA, MNKD, OREX, VVUS
Read
E Orexigen Gets An Early Morning Surprise With FDA Delay For Contrave
Article By: Terry Chrisomalis Wednesday, June 11, 2014 8:58 AM EDT
The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.
In this article: ARNA, OREX, VVUS
Read
E Small Cap Report: Best And Worst
Article By: E.B. Capital Markets Friday, April 11, 2014 10:16 AM EDT
The average small cap score is 47.75 this week, below the four week moving average score of 51.67. The average small cap stock is trading 23.9% below its 52 week high, 0.36% above its 200 dma, and has 7.05 days to cover short.
In this article: BLT, CDE, EPL, EXAM, FSS, GB, MED, NWY, ALIM, ALVR, ANEN, ARTC, OREX, VASC, CMTL, HWAY, MTEX, SWHC, CYTR, IWM, SPY
Read
Watch And Wait Wednesday – Show Us 10,500!
Article By: Phil Davis Wednesday, March 5, 2014 9:32 AM EDT
There's a war on folks, and it's not going on in the Ukraine or Afghanistan – it's a war right here in the USA between the top 1% and everyone else.
In this article: BAC, BRK-B, DIS, GE, HSBC, TGT, ARNA, OREX, AMZN, TSLA, BDSI, PCYC, SNSS, THLD, TZA, SPX, SCTY
Read
1 to 13 of 13 Posts